Diclofenac for Prevention of Post-ERC Pancreatitis

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

1,000

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Common Bile Duct Diseases

Interventions

DRUG

Diclofenac

Diclofenac rectally given before the ERCP to prevent pancreatitis

All Listed Sponsors

collaborator

Uppsala University

OTHER

lead

Karolinska Institutet

OTHER

NCT03595150 - Diclofenac for Prevention of Post-ERC Pancreatitis | Biotech Hunter | Biotech Hunter